Corine Knorr1, Ladina Greuter1, Shlomi Constantini2, Itzhak Fried2, Uri Kremer3, Alexandre N Datta4, Raphael Guzman1,5, Jehuda Soleman6,7,8. 1. Department of Neurosurgery and Division of Pediatric Neurosurgery, Children's University Hospital of Basel (UKBB), Basel, Switzerland. 2. Departments of Neurosurgery and Pediatric Neurosurgery, Tel Aviv Medical Center and Dana Children's Hospital, Tel Aviv University, Tel Aviv, Israel. 3. Department of Pediatric Neurology, Dana Children's Hospital, Tel Aviv University, Tel Aviv, Israel. 4. Department of Pediatric Neurology, Children's University Hospital of Basel (UKBB), Basel, Switzerland. 5. Faculty of Medicine, University of Basel, Basel, Switzerland. 6. Department of Neurosurgery and Division of Pediatric Neurosurgery, Children's University Hospital of Basel (UKBB), Basel, Switzerland. jehuda.soleman@gmail.com. 7. Departments of Neurosurgery and Pediatric Neurosurgery, Tel Aviv Medical Center and Dana Children's Hospital, Tel Aviv University, Tel Aviv, Israel. jehuda.soleman@gmail.com. 8. Faculty of Medicine, University of Basel, Basel, Switzerland. jehuda.soleman@gmail.com.
Abstract
OBJECTIVE: Vagal nerve stimulator (VNS) implantation at an early age seems to lead to improved quality of life and cognitive outcome. The aim of this analysis is to evaluate whether specific patient or seizure characteristics might lead to better seizure control, cognitive outcome, and higher quality of life in children undergoing VNS implantation. METHODS: Primary outcome measure was reduction in seizure frequency. Secondary outcome measures were epilepsy outcome assessed by McHugh and Engel classifications, reduction in antiepileptic drugs (AED), developmental and cognitive outcome, as well as quality of life assessed through the pediatric quality of life (PEDSQL™) questionnaire and care giver impression (CGI) scale. Forty-five consecutive children undergoing VNS implantation were analyzed for the following subgroups: age (categorized to 1-2 years old, 3-5 years old, 6-12 years old, and 13-18 years old), sex, underlying cause (categorized to idiopathic, encephalitis, stroke, syndromic), duration of preoperative seizures (dichotomized to under or above 89 months, corresponding to the median of the whole cohort), and preoperative seizure frequency (dichotomized to under and above 360 seizures per month). RESULTS: Encephalitis as the underlying cause for seizures was the only variable significantly associated with higher reduction rate of seizure frequency. Patients with VNS implantation at the age of ≤ 2 years showed a strong association with better developmental and cognitive outcome, as well as quality of life. Shorter duration of preoperative seizures and higher preoperative seizure frequency showed a strong association with better developmental outcome, as well as quality of life. Engel outcome scores were significantly better in patients with epilepsy due to encephalitis (100% Engel I-III). However, patients with epilepsy due to encephalitis showed significantly higher complication rates (71.4%, p = 0.045). CONCLUSIONS: Children suffering from epilepsy due to encephalitis show higher seizure reduction rates after VNS implantation when compared with children suffering from epilepsy due to other causes. Developmental and cognitive outcomes as well as quality of life of children undergoing VNS implantation is strongly associated with shorter duration of preoperative seizures and implantation at a young age.
OBJECTIVE: Vagal nerve stimulator (VNS) implantation at an early age seems to lead to improved quality of life and cognitive outcome. The aim of this analysis is to evaluate whether specific patient or seizure characteristics might lead to better seizure control, cognitive outcome, and higher quality of life in children undergoing VNS implantation. METHODS: Primary outcome measure was reduction in seizure frequency. Secondary outcome measures were epilepsy outcome assessed by McHugh and Engel classifications, reduction in antiepileptic drugs (AED), developmental and cognitive outcome, as well as quality of life assessed through the pediatric quality of life (PEDSQL™) questionnaire and care giver impression (CGI) scale. Forty-five consecutive children undergoing VNS implantation were analyzed for the following subgroups: age (categorized to 1-2 years old, 3-5 years old, 6-12 years old, and 13-18 years old), sex, underlying cause (categorized to idiopathic, encephalitis, stroke, syndromic), duration of preoperative seizures (dichotomized to under or above 89 months, corresponding to the median of the whole cohort), and preoperative seizure frequency (dichotomized to under and above 360 seizures per month). RESULTS: Encephalitis as the underlying cause for seizures was the only variable significantly associated with higher reduction rate of seizure frequency. Patients with VNS implantation at the age of ≤ 2 years showed a strong association with better developmental and cognitive outcome, as well as quality of life. Shorter duration of preoperative seizures and higher preoperative seizure frequency showed a strong association with better developmental outcome, as well as quality of life. Engel outcome scores were significantly better in patients with epilepsy due to encephalitis (100% Engel I-III). However, patients with epilepsy due to encephalitis showed significantly higher complication rates (71.4%, p = 0.045). CONCLUSIONS: Children suffering from epilepsy due to encephalitis show higher seizure reduction rates after VNS implantation when compared with children suffering from epilepsy due to other causes. Developmental and cognitive outcomes as well as quality of life of children undergoing VNS implantation is strongly associated with shorter duration of preoperative seizures and implantation at a young age.
Authors: Anne T Berg; Courtney Wusthoff; Renée A Shellhaas; Tobias Loddenkemper; Zachary M Grinspan; Russell P Saneto; Kelly G Knupp; Anup Patel; Joseph E Sullivan; Eric H Kossoff; Catherine J Chu; Shavonne Massey; Ignacio Valencia; Cynthia Keator; Elaine C Wirrell; Jason Coryell; John J Millichap; William D Gaillard Journal: Epilepsy Behav Date: 2019-06-07 Impact factor: 2.937
Authors: Andreas V Alexopoulos; Prakash Kotagal; Tobias Loddenkemper; Jeffrey Hammel; William E Bingaman Journal: Seizure Date: 2006-07-20 Impact factor: 3.184
Authors: Robert E Elliott; Shaun D Rodgers; Luigi Bassani; Amr Morsi; Eric B Geller; Chad Carlson; Orrin Devinsky; Werner K Doyle Journal: J Neurosurg Pediatr Date: 2011-05 Impact factor: 2.375
Authors: Charles F Yates; Kate Riney; Stephen Malone; Ubaid Shah; Liam G Coulthard; Robert Campbell; Geoff Wallace; Martin Wood Journal: Acta Neurochir (Wien) Date: 2021-11-10 Impact factor: 2.216